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Background: MicroRNAs were enrolled in various cardiovascular disease especially ischemic heart diseases, but the
microRNA changes during myocardial ischemia reperfusion injury underwent cardiopulmonary bypass are still
unknown. This study screens the microRNA differences in CPB canines and evaluates the relationship of microRNAs
with myocardial ischemia reperfusion injury.
Methods: 13 healthy canines received CPB with 60 minutes of aortic clamping and cardioplegic arrest, followed by
90 minutes reperfusion. Left ventricular myocardial samples, blood samples and hemodynamic data were taken at
different time points. We performed microRNAs microarray experiments upon the left ventricle myocardium tissue
of canines before CPB and after reperfusion for 90 minutes by pooling 3 tissue samples together and used qRT-PCR
for confirmation.
Results: Statistically significant difference was found in mir-499 level before CPB and after reperfusion (T1 vs. T4,
p = 0.041). We further examined the mir-499 levels by using qRT-PCR in all 13 canines at 4 different time points
(T1 vs. T4, p = 0.029). Mir-499 expression was negatively correlated with cardiac troponin T (cTnT) and creatine
kinase- MB (CK-MB) levels of canines in all time points samples (r = 0.469, p < 0.001 and r = 0.273, p = 0.050
respectively). Moreover, higher mir-499 expression level was associated with higher dP/dtmax at 25 minutes and
90 minutes after reperfusion.
Conclusion: Myocardial ischemic reperfusion injury with cardiopulmonary bypass results in declining level of mir-
499 expression in left ventricle myocardium of canines, suggesting mir-499 would be a potential therapeutic
target in cardiac protection during open heart surgery.
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MicroRNAs are short non-coding RNAs which are
about 18–25 nucleotides long and act as negative or
positive regulators, primarily post-transcriptionally [1,2].
They have enrolled in various pathological conditions,
especially cardiovascular disease [3], including ischemic
heart disease [4], heart failure [5], cardiac hypertrophy* Correspondence: wuzhk@mail.sysu.edu.cn
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reproduction in any medium, provided the or[6] and arrhythmias [7]. Recent studies have demon-
strated that there are significant expression profile
changes in a bunch of microRNAs in both ischemic/nor-
mal heart tissues [8] and peripheral blood [9]. Moreover,
some microRNAs perform biological functions of
protecting or damaging cardiac cells in myocardial ische-
mia through different pathways, particularly apoptosis,
which brings the treatment potency in the field of
microRNAs [4,10-12].
Recently, the microRNA expression patterns in acute
myocardial infarction have been fully elucidated [8,13].
However, the expression profiles of microRNAs in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been studied. We hypothesized that there are changes in
the level of microRNAs in cardioplegic heart compared
to their baseline. Those microRNAs might be potential
targets for myocardial protection in CPB. To testify this
hypothesis, we analyzed the expression of a broad range
of microRNAs using quantitative stem-loop RT-PCR ar-
rays on left ventricular samples at different IR time
points in CPB canines, and the clinical relevance of




The investigation conforms to the Guide for the Care
and Use of Laboratory Animals (NIH publication no.
85–23, revised 1996). All procedures were approved by
the Committee on the Ethics of Animal Experiment of
the First Affiliated Hospital of Nanjing Medical Univer-
sity (Approval No. 2010CB5295007). All reasonable ef-
forts were made to minimize suffering.
Experimental protocol
Thirteen healthy adult canines (2–3 years old, weight
18.8 ± 2.16 kg, Suibei Nursery of Laboratory Animals,
Baiyun District, Guangzhou) of both genders are col-
lected. All animals accepted 60 minutes of aortic
clamping and cardioplegic arrest. CPB was weaned off
after reperfusion. Blood and myocardial samples from
the radial artery were collected at designated time points
(T1: Baseline, after thoractomy, T2: at 60 minutes after
aortic clamping, T3: at 25 minutes after reperfusion, and
T4: at 90 minutes after reperfusion; Figure 1).
Anesthesia and monitoring
The canines were anesthetized with an intramuscular ad-
ministration of ketamine (30 mg/kg, JiuXu Pharmaceutical
Co. Ltd, Zhejiang, China), fentanyl citrate (2 μg/kg, RenFu
Pharmaceutical Co. Ltd, Yi 105 Chang, China), and
an intravenous administration of vecuronium bromide
(0.1 mg/kg, SiDa Pharmaceutical Co. Ltd, Hainan, China)
[14]. Tracheal intubation was performed, and mechanicalFigure 1 Experimental protocol. T1: Baseline, after thoractomy, T2:
at 60 minutes after aortic clamping, T3: at 25 minutes after
reperfusion, and T4: at 90 minutes after reperfusion.ventilation was started at a tidal volume of 15 mL/kg
body weight 110 and a rate of 15 breaths per minute
using a volume cycled respirator (BIRD VELA, Model
606A, USA). The anesthesia was maintained with intra-
venous infusion of fentanyl, vecuronium bromide, and
midazolam. The anesthesia protocol is consistent with
the guidance of National Research Council Staff. Fluid-
filled catheters were then placed into the left femoral ar-
tery for mean arterial pressure (MAP) monitoring and
blood sampling. Fluid administration was carried out
through cannulation of the left femoral vein. Blood pres-
sure were monitored and recorded by a 16 channel chart
recorder (BIOPAC MP150, California, USA).
Cardiopulmonary bypass
CPB was performed using one roller pump for extracor-
poreal circulation and another roller pump for suction.
We primed the extracorporeal circuit and the membrane
oxygenator (AFFINITY NT 541, Medtronic Inc, USA)
with canine blood (average 585 ± 76.97 mL) and multiple
electrolyte injections. The total priming volume was ap-
proximately 1500 mL. The priming blood was derived
from another 13 canines under general anesthesia.
Heparin (XinYi Pharmacectic Manufactory of Shanghai
Medicine Group, Shanghai) was added to the blood
(300U/100 mL) and crystal liquid (200U/100 mL). No
other medications were given to minimize any potential
cross-reactions. Following preparation, heparin (300U/
kg) was given intravenously for systemic anticoagulation.
An 18 F arterial perfusion cannula was introduced into
the aorta, while two 18 F venous cannulas (Edwards
Lifesciences LLC, Irvine, USA) were placed into the
right atrium and inferior vena cava, via median
sternotomy. After CPB was achieved, cardiac arrest was
induced by antegrade injection of homemade cold 4°C
crystalloid cardioplegia (10% potassium chloride 7 mL,
25% magnesium sulfate 1.4 mL, 50% glucose 10 mL,
20% mannitol 5 mL, 5% sodium bicarbonate 18 mL, 2%
lidocaine 10 mL, and 4 mg dexamethasone, with Ringer’s
injection added to a total volume of 500 mL). Electric
defibrillation was used if necessary after aortic
declamping. Activated clotting time was maintained
for more than 480 seconds. The MAP was controlled
between 70 and 90 mmHg. The nasopharyngeal
temperature was maintained at 36°C by a heat exchan-
ger (Sarns Heater/Cooler, Ann Arbor, MI, USA).
Myocardial biochemical markers determination
At T1, T2, T3, and T4, the blood sample was centrifuged
and serum was extracted to measured the levels of
cardiac Troponin T (cTnT) and creatine kinase- MB
(CK-MB) using a high-sensitivity cardiac troponin T en-
zyme linked immunosorbent assay kit (USCN Life
Science, Wuhan, CHN). Samples of myocardium from
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system (Bard MAGNUM REF/Cat.No. MG1522).
Measurement of cardiac function and hemodynamic
parameters
A water-filled latex balloon attached to a pressure sensor
(model SP844; MEMSCAP Inc., Durham, NC) was
inserted into the left ventricle through the left atrium
and mitral valve. Blood pressure, maximum left ven-
tricular developed pressure increase (dP/dt max) and
decrease rate (dP/dt min) were monitored and recorded
at T1, T2, T3 and T4 by a 16-channel chart re-
corder (BIOPAC MP150, California, 125 USA) .2.7
RNA isolation.
Total RNA was isolated from heart tissue with LCS
total RNA extraction kit (TRK-1002) and with this kit
genomic DNA contamination can be removed by the
process of on column DNase I digestion at room
temperature for 15 min, after a series of wash steps the
purified total RNA was eluted with elution solution.
Microarray analysis
For microRNAs microarray analysis, total RNA from 3
left ventricle samples of T1, and 3 samples of T4 (each
T1 and T4 is paired to each canines) was isolated. After
the isolation, 3 different sample of T1, each 2.5 ug total
RNAs were mixed together as a pooling sample, com-
pared with mixed 3 sample of T4. Profiling of miRNAs
expression was analyzed by LC Sciences on their micro-
array platform using Sanger miRBase Release 17.0
database (http://microrna.sanger.ac.uk/sequences/).
The assay started from 10 μg total RNA sample, which
was size fractionated using a YM-100 Microcon centrifu-
gal filter (from Millipore) and the small RNAs (< 300 nt)
isolated were 3’-extended with a poly(A) tail using poly
(A) polymerase. An oligonucleotide tag was then ligated
to the poly(A) tail for later fluorescent dye staining;
Hybridization was performed overnight on a μParaflo
microfluidic chip using a micro-circulation pump
(Atactic Technologies) [15,16]. On the microfluidic chip,
each detection probe consisted of a chemically modified
nucleotide coding segment complementary to target
microRNA (from miRBase, http://microrna.sanger.ac.uk/
sequences/) or other RNA (control or customer defined
sequences) and a spacer segment of polyethylene glycol
to extend the coding segment away from the substrate.
The detection probes were made by in situ synthesis
using PGR (photogenerated reagent) chemistry. The
hybridization melting temperatures were balanced
by chemical modifications of the detection probes.
Hybridization used 100 μL 6 × SSPE buffer (0.90 M
NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8)
containing 25% formamide at 34°C. After hybridization
detection used fluorescence labeling using tag-specificCy5 dyes. Hybridization images were collected using a
laser scanner (GenePix 4000B, Molecular Device) and
digitized using Array-Pro image analysis software (Media
Cybernetics). Data were analyzed by first subtracting the
background and then normalizing the signals using a
LOWESS filter [17] (Locally-weighted Regression). Higher
signal indicates higher microRNA expression.
Real-time PCR
10 microRNAs are selected after microarray analysis and
that primers are listed in Tables 1 and 2. For Reverse
transcriptase reactions it contained 250 ng total RNA,
1uM stem-loop RT primer, 5× RT buffer,10 mM each
dNTPs, 40 U/ul RNase inhibitor and 200 U/ul M-MLV.
Reaction mixtures were incubated in an ABI PRISM®
7900HT for 60 min at 42°C, 15 min at 70°C, and held at
4°C. Reverse transcriptase reactions including no-template
controls and RT-minus controls were run in duplicate.
Real-time PCR was performed using Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen). The reaction
mixtures were incubated in a 96-well plate at 95°C for
30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C
for 30 sec. All reactions were run in triplicate. To account
for possible differences in the amount of starting RNA,
microRNA expressions were normalized to small RNU6B,
with the similar efficiency of microRNAs [18,19]. Data of
qRT-PCR were demonstrated by nominal CT value (nor-
malized to RNU6B), and fold changes were calculated
by 2^|△△CT|. Higher nominal CT value means lower
microRNA expression level.
Statistical analysis
All values are presented as mean ± standard deviation.
Results of cardiac enzymes, hemodynamic parameter
changes, microarray and qRT-PCR results between time
intervals were analyzed by paired t test. Spearman cor-
relation coefficients were used to examine the rela-
tionship between miR-499 and cardiac enzymes levels.
P < 0.05 was considered statistically significant.
Results
Myocardial biochemical markers changes during
cardiopulmonary bypass and reperfusion
As demonstrated in Figure 2A and B, the level of cTnT
and CK-MB level in blood was raised during ischemia
and reperfusion. The level of cTnT in T1, T2, T3, T4
were 0.015 ± 0.020, 0.707 ± 0.392, 1.356 ± 0.694, 3.771 ±
3.864 ng/ml respectively and the level of T2, T3 and T4
were significantly higher than T1 respectively (T1 vs. T2,
p < 0.001; T1 vs. T3, p < 0.001; T1 vs. T4, p < 0.001). The
level of CK-MB in T1, T2, T3, T4 were 357.46 ± 311.85,
1311.92 ± 667.58, 1667.31 ± 808.39, 2165.46 ± 1050.63 ng/
ml and the level of T2, T3 and T4 were significantly higher
Table 1 Primers for reverse transcription of microRNAs
No. Assay name Gene Bank/miRbase Access No. Primers for reverse transcriptase Sequence(5' to 3')
1 cfa-miR-451 MIMAT0009870 AAACCGUUACCAUUACUGAGUU
2 cfa-miR-423 MIMAT0006742 UGAGGGGCAGAGAGCGAGACUUU
3 cfa-miR-23 MIMAT0006640 AUCACAUUGCCAGGGAUUU
4 cfa-miR-133 MIMAT0009835 UUUGGUCCCCUUCAACCAGCUA
5 cfa-miR-489 MIMAT0009860 GUGACAUCACAUAUACGGCGGC
6 cfa-miR-574 MIMAT0006673 CACGCUCAUGCACACACCCACA
7 cfa-miR-214 MIMAT0009847 ACAGCAGGCACAGACAGGCAGU
8 cfa-miR-1 MIMAT0006656 UGGAAUGUAAAGAAGUAUGUA
9 cfa-miR-494 MIMAT0009905 UGAAACAUACACGGGAAACCUC
10 cfa-miR-499 MIMAT0006655 UUAAGACUUGCAGUGAUGUUU
Control human-RNU6B NR_002752
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p < 0.001; T1 vs. T4, p < 0.001).
Microarray results
Microarray data mining and differential analyses of ex-
pression of microRNAs has found 19 significantly
changed microRNAs associated with ischemia and reper-
fusion in CPB animals in the left ventricular myo-
cardium with CPB and reperfusion (T1/T4) (Table 3).
Mir-451, mir-1, mir-489, mir-133b/c, mir-143, mir-30b
/c, mir-191, mir-22 are down regulated, whereas mir-
423a, mir-494, mir-214, mir-574, mir-23a/b, let-7e, mir-
499, mir-24 are up regulated.
Confirmation of the altered expression of microRNAs by
qRT-PCR
To verify the accuracy of the microarray results above,
we selected 10 of the 19 deregulated microRNAs
according to relatively lower P value in microarray or its
association to myocardial infarction by various re-
searches. For further confirmation, qRT-PCR test was
used in 3 pair samples. Only changes in cfa-mir-499Table 2 Primers for real time PCR











human-RNU6B CAAATTCGTGAAGCGTTCbetween T1 and T4 had reached statistical significance
(p = 0.041) (Table 4).Mir-499 expression among different time points
Mir-499 expression was examined in 4 different time
points in all 13 canines. As shown in Figure 3, the
mir-499 expression levels in T4 (at 90 minutes after
reperfusion) were significantly lower than those in T1
(p = 0.029). There’re no statistical differences between
T1and T2 (p = 0.821), so does T1 and T3 (p = 0.577).Correlation of mir-499 expression and cTnT levels at all
time points
Because of high degree of dispersion, we use nominal
CT value instead of fold changes in correlation analysis
(Figure 4A and B). Nominal CT value of mir-499 were
positively correlated with cTnT and CK-MB levels at all
time points (r2 = 0.469, p < 0.001 and r2 = 0.273, p = 0.050
respectively), indicating that the higher the cTnT and
CK-MB in blood, the lower the mir-499 expression level in












Figure 2 (A and B) The levels of blood CK-MB and cTnT are
significantly increased after CPB and reperfusion. P <0.001 were
found between T1 vs.T2, T1vs.T3, T1vs.T4.
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A cut-off value was set in the median level of mir-499
expression in T3 by nominal CT value and divided 13
canines into 2 groups. The hemodynamic parameters be-
tween groups were compared using paired t test. As
shown in Table 5, higher mir-499 expression level in T3
is associated with higher dP/dtmax (maximum left ven-
tricular developed pressure increase rate) in T3 and
higher dP/dtmax in T4.
Discussion
Our study provides evidence that several microRNAs’
level change during myocardial IR injury in CPB canines,which are found in left ventricular myocardiums using
microRNA array with pooling samples. Mir-1, mir-494,
mir-133, mir-499, mir-214 have been reported to be associ-
ated with acute myocardial infarction [8,11,13,20-22]. Some
of the altered microRNAs were reported to be related to
apoptosis (mir-191 [23], mir-22 [24], mir-30 [25], mir-24
[26]), hypoxia(mir-451 [27], mir-23 [28]) and cell prolifera-
tion(mir-489 [29], let-7e [30]). These results indicate that a
bunch of microRNAs may take part in response to myocar-
dial IR injury. Among aberrantly expressed microRNAs in
microarray which were verified by qRT-PCR, mir-499 was
found to be a significantly down-regulated microRNA at
90 minutes following reperfusion exclusively. However, the
qRT-PCR shows ambivalent results in mir-499 expression
compared with results given by microarray. Possible rea-
sons included the disturbance of pooling sample, and the
relative inaccuracy of microarray. The present study is the
first report to address cardiac microRNAs in a clinical rele-
vant CPB model. Furthermore, there is a moderate negative
correlation between mir-499 level, cardiac enzymes levels
and hemodynamic parameters, which supports previous
studies that mir-499 is in association with cardiomyocytes
damage and prognosis. Therefore, our results imply that
mir-499 might possibly be a potential therapeutic target of
myocardial protection during CPB surgery.
Recently, it was reported that myocardial infarction re-
sults in great changes of microRNAs level in myocar-
dium and peripheral blood among patients and animal
models [8,9,21]. The molecular mechanisms regulating
microRNA expression in cardiac ischemia and reperfu-
sion remain largely unknown [31]. However, such patho-
physiological conditions closely related to cardiomyocyte
apoptosis through which specific microRNAs took roles
in preventing and maintaining an effect of cardio-
protection [32]. For instance, mir-494 is down regulated
in ischaemic hearts and has a cardioprotective effects by
activating the Akt pathway [20]. Mir-133 produces
opposing effects on apoptosis by targeting heat shock
protein 60/70 and caspase-9 in cardiomyocytes [33].
Notwithstanding, most of current studies are base on
the model of index heart ischemia mimicking acute cor-
onary syndrome, but the changes in cardiopulmonary
bypass still remain uncertain. Recent findings suggest
that serum and urine mir-1 act as biomarker of myocar-
dial injury with cardiopulmonary bypass [34]. CPB can
trigger apoptosis during cardiac surgery by a series of
mechanisms, including ischemia, oxidative stress upon
reperfusion, contact with CPB circuit material, pro-
inflammatory cytokines, etc. [35,36]. Most of the myo-
cardial IR injury in CPB are stunning while myocardial
infarction are more common in acute coronary syndrome
[37]. Malmberg discovered that short and unprotected
warm ischemia produces much more cardiomyocytes
apoptosis than a longer period of protected cold ischemia
Table 3 MicroRNAs differentially expressed in IR




Fold change P value
cfa-miR-451 2239/548 0.24 1.07E-14
cfa-miR-1 10512/1379 0.13 1.09E-13
cfa-miR-423a 440/768 1.74 1.38E-10
cfa-miR-494 271/1914 2.82 2.80E-10
cfa-miR-489 791/386 7.06 2.05E-09
cfa-miR-214 382/632 1.65 2.37E-09
cfa-miR-574 318/1020 3.20 4.55E-09
cfa-miR-133c 3782/2612 0.69 1.19E-08
cfa-miR-143 1223/853 0.69 4.91E-08
cfa-miR-133b 3502/2515 0.71 3.64E-07
cfa-miR-23a 914/1467 1.60 3.94E-07
cfa-miR-30c 1436/823 0.57 1.40E-06
cfa-let-7e 518/981 1.89 2.90E-06
cfa-miR-23b 663/1197 1.80 5.52E-06
cfa-miR-499 1012/1296 1.28 8.70E-04
cfa-miR-191 964/831 0.86 1.41E-03
cfa-miR-30b 756/572 0.75 1.63E-03
cfa-miR-22 1732/1493 0.86 1.77E-03
cfa-miR-24 3381/3759 1.11 2.71E-03
Microarray analysis showed that totally 19 microRNAs were altered, in which
10 microRNAs were down-regulated and 9 microRNAs were up-regulated.
Figure 3 A comparison of fold changes based on qRT-PCR
analysis of mir-499 of 4 time points. (T1 vs. T4). Mir-499 was
down-regulated after 90 minutes reperfusion (T4) compared with
baseline (T1). (*P = 0.029).
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myocardial ischemia can’t be simply utilized in myocardial
IR injury of CPB models. Our results demonstrated that
among several microRNAs which were found fluctuating
following IR injury, only mir-499 was down-regulated.
Mir-1, mir-494, mir-133, which shown significant changesTable 4 microRNA differentially expressed in control and
after CPB/ reperfusion










Mir-499 was found down-regulated at 90 minutes after reperfusion (T4)
compared with Baseline (T1) in 3 pair samples by qRT-PCR. Significant change
was found in mir-499 expression level (P < 0.05).
Figure 4 (A and B) Correlation plots between cTnT, CK-MB
levels and mir-499 nominal CT values in all 52 samples (all 4
time points). Higher CT value means lower mir-499 expression. The
higher the cardiac enzymes, the higher the nominal CT value of mir-
499 thus the lower the mir-499 expression level. (A) mir-499 vs. cTnT
(r = 0.469, p < 0.001). (B) mir-499 vs. CK-MB (r = 0.273, p = 0.050).
Table 5 Association between mir-499 level in T3 and hemodynamic parameters
T3 p-value T4 p-value
Mean dP/dtmax with higher mir-499 expression (mmHg) 1107.86 ± 318.10 0.009 1116.00 ± 310.10 0.019
Mean dP/dtmax with lower mir-499 expression (mHg) 620.67 ± 215.58 629.33 ± 326.55
Mean dP/dtmin with higher mir-499 expression (mmHg) 605.57 ± 369.99 0.209 645.29 ± 328.58 0.076
Mean dP/dtmin with lower mir-499 expression (mmHg) 360.60 ± 273.99 321.00 ± 256.24
Higher mir-499 expression level in T3 is associated with higher myocardial systolic function in T3 and T4. dP/dt max = maximum left ventricular developed pressure
increase rate; dP/dt min = maximum left ventricular developed pressure decrease rate.
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Mir-499 is a cardiac ventricular abundant microRNA
under physiological condition and evolutionarily con-
served among species [38-42]. It is encoded by β-myosin
heavy chain gene (Myh7b) [43,44] and shown a pivotal
role in inhibiting cardiomyocytes apoptosis. Researchers
noted that mir-499 was down regulated in myocardial is-
chemia in rats [22] and correlated to the severity of
cardiomyocytes damage [45]. However, our results show
that mir-499 fail to decrease after clamping the aorta for
60 minutes. Such phenomenon might origin from the pro-
tection effect of hypothermia and cardiaplegic arrest. At
90 minutes after reperfusion, the mir-499 level decrease
significantly compared with baseline. This is the first time
to demonstrate that mir-499 related to CPB myocardial re-
perfusion injury, rather than ischemia injury. Furthermore,
Mir-499 targets alpha, beta isoforms of the calcineurin
catalytic subunit and dynamin-related protein-1 (Drp1) in
mitochondria during myocardial infarction [22], suggesting
that mitochondrial activation pathway takes an important
role in cardiomyocytic apoptosis after reperfusion in CPB,
which is accordance with previous reports [46].
In the present study, we observed that lower myocar-
dium level of mir-499 was associated with poorer car-
diac systolic function during reperfusion than their
counterparts. What’s more, mir-499 level in myocar-
dium negatively correlated to cTnT level of peripheral
blood, giving a clue that myocardial level of mir-499
might reflect the degree of cardiomyocyte damage.
Elevated level of mir-499 in blood of coronary sinus was
discovered from patients suffering from troponin-positive
acute coronary syndromes and significantly correlated to
hsTnT [45]. Moreover, plasma mir-499 was identified as a
biomarker and prognostic factor in acute myocardial in-
farction [47,48]. Our results confirm and extend the con-
cept of mir-499 in previous reports, showing that the
decrease of mir-499 in myocardium might be associated
with myocardial injury with a significant release of
microRNAs into peripheral circulation.
Conclusions
In principle, the present findings support the hypoth-
esis that microRNAs expression level can be influencedby IR injury in CPB models and IR injury resultes in a
decreased level of mir-499 during reperfusion. Lower
mir-499 level correlated to more severe IR injury and
poor hemodynamic performance. However, the mech-
anism between microRNAs and IR injury in CPB are
not fully understood. Whether the decreased expres-
sion level of mir-499 after reperfusion is the cause or
the consequence of myocardial injury is still uncertain.
We used pooling sample which may diminished the
differences for microRNAs array and decrease the sen-
sitivity to examine the unknown microRNAs which
participated in IR injury mechanism. Our present study
suggested that the introduction of mir-499 as a poten-
tial therapeutic method of myocardial protection in
open heart surgery would be possible but still wait for
further studies.
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